ZBTB7A and cancer: Recent studies in which PFKP expression was indirectly increase or decrease either via the ZBTB7A transcriptional repressor or by sorafenib have suggested that PFKP might be a suitable drug target for anti-cancer therapies as inhibition of PFKP represses aerobic glycolysis [51, 52].